Browse Tag


3 mins read

Somatus: A Billion-Dollar Disruptor in Kidney Care

Somatus, a Virginia-based healthcare company, is revolutionizing the way kidney disease is managed.

Founded in 2016 by Dr. Ikenna Okezie, the company has become a leader in value-based kidney care, prioritizing prevention and empowering patients to take control of their health.

Somatus identified a gap in traditional care, which often focuses on dialysis for late-stage kidney disease. Their model flips the script, emphasizing early detection and prevention. The company’s secret weapon? The proprietary RenalIQ platform. This AI-powered platform uses machine learning and analytics to track patient health, identify at-risk individuals, and offer telehealth and virtual care options.

Somatus further strengthens its approach through partnerships with local nephrologists, primary care physicians, and health plans. This multi-disciplinary approach ensures patients receive personalized, in-home care and the knowledge they need to manage their condition effectively.

In 2022, Somatus served over 150,000 members across various healthcare plans. That same year they secured over $325 million in Series E funding. This deal was ranked as one of the biggest healthcare VC deals of 2022, valuing the company at over $2.5 billion.

“Since our inception, Somatus has always been committed to bringing superior evidence-based integrated care to patients with kidney disease, which delays disease progression, improves quality of life, and lowers total cost of care,” Okezie said when announcing the Series E funding round. “This investment puts us in a great position to fund the expansion of our proven care model and continue building a nationwide network of providers and connected patients, who alongside our care teams are working together to improve lives and transform the industry.”

In June 2023, Somatus announced a significant expansion of their existing collaborative efforts with Kidney Care Center. This multi-state partnership leverages Somatus’s VBC (value-based care) model, Care Coordination (CKCC), and joint venture arrangements to enhance patient care through a local care team, advanced technology, and direct medical care.

Furthermore, Somatus signed the Health Evolution Pledge in October 2023, demonstrating their commitment to leveraging data to address health disparities and improve access to care in underserved communities.

In February 2024, Somatus was selected as a preferred partner by Sun Life U.S. to deliver a unique care model for their stop-loss members with late-stage kidney disease and heart disease. This collaboration aims to improve patient health outcomes while reducing costs through AI-driven medication management, care coordination, nutritional support, and transitions of care, aligning with Sun Life’s Clinical 360 program focused on data analytics to enhance outcomes.

With groundbreaking technologies and strategic partnerships, they offer hope to millions affected by CKD, promising a new era of compassionate healthcare. This impact is particularly significant given that over 37 million Americans have CKD, underscoring the potential of Somatus’s work.

by Tony O. Lawson

➡️ Advertise with us

Don’t miss any articles! Subscribe to our newsletter and follow us on Facebook, Instagram, LinkedIn & Twitter.

3 mins read

Health In Her HUE Raises $3 Million to Bridge Racial Health Disparities

Health In Her HUE is a digital health platform dedicated to tackling racial health disparities for Black women and women of color. The company recently announced the successful closure of a $3 million seed funding round, marking a pivotal moment in its mission to revolutionize healthcare access through technology and community-driven initiatives.

Founded in 2018 by Ashlee Wisdom, Health In Her HUE emerged with a clear goal: to create a supportive ecosystem that empowers women of color by connecting them with culturally responsive healthcare providers and vital health-related information.

Health In Her HUE

This funding round, led by Seae Ventures, includes backers such as Johnson & Johnson Impact Ventures, Morgan Stanley Inclusive Ventures Lab, Genius Guild, HBCU Founders Fund, Stanford Impact Fund, and a group of angel investors.

Health In Her HUE’s platform includes an array of offerings aimed at addressing the unique healthcare needs of its nearly 13,000 members. The platform encompasses a comprehensive directory featuring over 1,300 diverse healthcare providers across 60 specialties. This directory empowers members to personalize their healthcare journey by connecting with providers who understand and cater to their cultural nuances and individual requirements.

Furthermore, the platform offers an extensive collection of educational health content through various mediums, including long and short-form videos, articles, and live virtual events. These resources serve as informative tools, ensuring women remain informed and engaged in managing their healthcare effectively.

Central to its impact is the vibrant community fostered by Health In Her HUE. Forums and programs, such as the Care Squad Program, provide spaces for women to engage, learn from each other’s experiences, and access peer support groups curated by healthcare professionals. Topics range from fibroids and fertility to mental health, addressing critical issues often overlooked in conventional healthcare settings.

Wisdom expressed pride in the platform’s achievements and emphasized her firsthand understanding of the challenges faced by women of color within the healthcare system. Her vision to provide a safe and inclusive space where women feel seen and heard while receiving quality care has been the driving force behind Health In Her HUE’s growth and impact.

The success of this recent funding round marks the second significant investment received by the company, bringing the total investment to $4.2 million. It not only highlights investor confidence but also underscores the urgent need to address racial health disparities, acknowledging the pivotal role technology and community engagement play in effecting meaningful change.

by Tony O. Lawson

➡️ Advertise with us ⬅️

➡️Interested in investing in Black founders? Please complete this brief form.

11 mins read

Revolutionizing Cancer Care: The Innovative Approach of A28 Therapeutics

Dr. Stanley Lewis is the founder and CEO of A28 Therapeutics, a clinical-stage biopharmaceutical company focused on the development of its targeted lytic peptide platform for the treatment of cancer.

In this interview, Dr. Lewis discusses his inspiration for starting A28 Therapeutics, the company’s focus on targeted oncolytic peptides (TOPs), and the promise of AT-101 in the treatment of metastatic ovarian cancer with liver metastases and hepatocellular carcinoma. 

He also shares his advice for aspiring entrepreneurs and researchers looking to make a significant impact in the field of healthcare and biotechnology.

Can you tell us a bit about your background and what inspired you to start A28 Therapeutics?

I am an internal medicine physician by training. I graduated from the University of Texas McGovern Medical School in Houston and obtained a master’s degree in public health. After completing my internship, residency, and fellowship, I joined the faculty of the medical school in the Department of Internal Medicine. 

As an academic physician, I saw patients, taught students and residents, and conducted dozens of clinical trials. My area of interest was HIV/AIDS, and in my practice, I cared for mostly indigent patients in the Houston area. I was recruited from academia to join a small biotech company and lead a program for the development of a new treatment for HIV.  After quite a few twists and turns, we were fortunate to earn FDA approval for TROGARZO, the first long-acting medication for the treatment of multi-drug resistant HIV disease.

There are several reasons for founding A28 Therapeutics. First, I really take the Hippocratic Oath seriously. In particular, the commitment to “First, do no harm” really guides me. During those early days of treating HIV patients, the medicines were very difficult to tolerate.

I felt terrible that my patients had the unenviable choice of taking some very toxic medications to control the virus or not taking the medicines and dying of AIDS. This was the primary reason I agreed to develop TROGARZO as my clinical trial patients commented that it was perhaps the most tolerable medicine they had ever taken. 

In many ways, I see current cancer patients having to face a similar dilemma as they weigh the risks and benefits of enduring toxic chemotherapies in exchange for a few more months of life. At A28 Therapeutics, we want to change that. Our vision is a world where patients no longer fear cancer or its treatments.

My second reason for starting the company is rooted in the type of molecules we develop. Interestingly, cancer and infectious diseases have a lot in common. In particular, bacteria have negatively charged cell walls and have been treated with lytic peptides such as vancomycin for decades. In fact, your body makes lytic peptides as part of the immune system. Well, cancer cells are also negatively charged; so, why not treat them with lytic peptides? 

In many ways, our molecules are like antibiotics that have been retooled to treat cancer. I appreciated their unique mechanism of eliminating cancer and their remarkable tolerability. To me, lytic peptides are just what the infectious disease doctor ordered.  Hopefully, soon, lytic peptides will be just what the oncologist orders.

My final reason for founding this company is deeply personal. My father died of metastatic gastric cancer. It was his dream that his son become a doctor, but before I could graduate, he died of this terrible disease. Like many solid tumors, gastric cancer can be cured surgically if you can diagnose it early before it spreads. However, when my father was diagnosed, his tumor had spread to his liver, and he was only given three months to live. 

The medications we are developing at A28 have an interesting biodistribution pattern such that they accumulate and persist in the liver for three days. This high exposure in liver tissue is believed to make them particularly useful in patients who have cancer that has metastasized to the liver or originates in this organ. So, when I had the opportunity to develop a drug that could help people who, like my father, had metastatic disease to their liver, I knew that I hadn’t found this medication, it found me.

A28 Therapeutics is known for its focus on targeted oncolytic peptides (TOPs) for cancer treatment. Could you explain the concept of TOPs and what differentiates them from traditional cancer therapies?

Targeted Oncolytic Peptides are a combination of a hormone-targeting unit and a lytic peptide payload. Our first molecule, AT-101, is a 10-amino acid hormone (luteinizing hormone releasing hormone – LHRH) targeting unit combined with a highly positively charged 18-amino acid lytic peptide payload.  The LHRH hormone targeting unit binds to hormone receptors found on the surface of a myriad of different tumor types. This binding brings the positively charged lytic peptide in proximity to the negatively charged cancer cell membrane resulting in a disruption of the membrane and killing of the tumor cell.  An animation of this mechanism can be viewed on the website.

Healthy cells do not have a strong negative charge and therefore are not harmed by this medication. The most noteworthy side effect observed through Phase 2 clinical trials with AT-101 is a transient, treatable rash. Another feature that differentiates our lead compound from traditional chemotherapies is that the killing of tumor cells by lytic peptides causes the tumor cell to release its antigens. This type of cancer cell death alerts the immune system much like a vaccine allowing for amplification of cancer killing throughout the body.

Finally, in laboratory testing, AT-101 synergies with all manner of chemotherapy and newer immunotherapies and may even resensitize resistant tumor cells to chemotherapies that have stopped working.  When you think about all the ways you would want cancer therapy to work, AT-101 really has it all.

What motivated you to concentrate on developing AT-101, and how has it shown promise in the treatment of metastatic ovarian cancer with liver metastases and hepatocellular carcinoma?

For a variety of reasons, most solid tumors metastasize to the liver, and patients with liver metastases invariably have shorter life expectancy than patients without liver metastases. In addition to being remarkably well tolerated, in a retrospective analysis of the Phase 2 study, the subset of patients with metastatic ovarian cancer and liver metastases who received AT-101 plus paclitaxel (standard of care chemotherapy) vs paclitaxel alone, the AT-101 treated patients experienced a 61% increase in overall survival. 

We want to confirm this observation prospectively in our next trial. Additionally, we plan to test AT-101 in hepatocellular (liver) cancer because the molecule achieves high and prolonged concentrations in the liver allowing for potentially high anticancer activity.

What have been the most significant milestones or achievements for A28 Therapeutics thus far in its mission to transform cancer care?

A28 Therapeutics was recognized as a 2023 Cool Company by Connect San Diego.  This award is bestowed on companies considered to be the fastest and most exciting startups in Southern California.

What are the company’s top priorities for the next 12-18 months?

We are seeking to raise a $20M Series A round of financing to prospectively validate the retrospectively observed efficacy signal from the Phase 2 clinical trial. Our next trial is a 2-stage adaptive trial design. The first stage will confirm the efficacy signal, and the second stage will expand to a sufficient number of patients to support an application for accelerated approval.

What advice do you have for aspiring entrepreneurs and researchers looking to make a significant impact in the field of healthcare and biotechnology?

The most important thing I’ve learned is that there is no blueprint for this stuff. You must have integrity because lives depend on your honest and thoughtful assessments of data. 

You must be resilient because things will not always go as planned. You must be patient as it will always take longer and cost more than you expect. You should build a strong network because this is not something you can do alone.

And finally, it helps if you are passionate about your work. You will need this to drive and sustain you on this journey.

by Tony O. Lawson

4 mins read

Homer G. Phillips Hospital: A Beacon of Hope, Excellence, and Resilience

The Homer G. Phillips Hospital, a testimony to vision and determination, stands as an enduring symbol of progress, equity, and the pursuit of excellence in healthcare.

Built at a final cost of $3.16 million, this institution was not just a hospital; it was a beacon of hope for the African American community in St. Louis and beyond.

The hospital’s architectural grandeur was awe-inspiring. It’s main central administration building, surrounded by four radiant wings, was a demonstration of thoughtful design and functional efficiency. With a staggering 685 patient beds, the hospital was a lifeline for countless individuals, providing much-needed medical care to those who had long been marginalized.

Homer G. Phillips

Operating such a colossal facility required an army of dedicated professionals. The Homer G. Phillips Hospital employed approximately 800 individuals who worked tirelessly to ensure its smooth operation. Their commitment to the community they served was truly commendable, and they played an integral role in making the hospital a success.

But the hospital’s commitment to excellence did not stop at providing medical care. It recognized the importance of education and empowerment, not only for the individuals it served but also for aspiring Black medical professionals.

The hospital’s dedication to this cause was evident through the construction of a separate nurse’s home, providing dormitories for 147 nurses and 24 interns. This nurturing environment allowed these future medical leaders to focus on their studies and training without the added burden of finding suitable housing.

Homer G. Phillips

Upon its inception, the Homer G. Phillips Hospital instantly became the largest, best equipped, and most technologically advanced hospital exclusively dedicated to the medical care of a city’s Black population.

This distinction was not just a matter of size; it was a matter of empowerment and representation. African Americans in St. Louis finally had a healthcare institution that recognized their unique needs and challenges.

By 1941, the hospital embraced a new philosophy: to become a premier training ground for Black medical professionals. This commitment to education was nothing short of transformative. In just seven years after opening its doors, the hospital was already training one-third of the graduates from the two Black medical schools in the entire country. This was an astonishing accomplishment, and it spoke to the hospital’s dedication to shaping the future of healthcare by empowering talented individuals.

However, as progress often comes with its own set of challenges, the Homer G. Phillips Hospital faced its own trials. The hospital eventually closed its doors in 1979.

While the physical building may have ceased its operations, its impact and legacy live on, inspiring future generations of medical professionals and serving as a reminder of the power of commitment, determination, and the pursuit of equality.

Homer G. Phillips
Homer G. Phillips Nurses Alumni, Inc.

The legacy of the Homer G. Phillips Hospital is one that continues to inspire and remind us of the power of commitment, determination, and the pursuit of equality.

➡️ Advertise your Business

Don’t miss any articles! Subscribe to our newsletter and follow us on Facebook, Instagram, LinkedIn & Twitter.

2 mins read

After Decades of Fighting, Henrietta Lacks Family Finally Gets Some Justice

The family of Henrietta Lacks, a Black woman whose cells were used for groundbreaking medical research without her consent, has reached a settlement with Thermo Fisher Scientific, a company that used her cells without her consent. The settlement was announced on August 1, 2023.

The terms of the settlement are confidential, but the family’s lawyers say that it includes a financial payment and a commitment from Thermo Fisher to engage in outreach and education about the Lacks family’s story.

The settlement is a significant victory for the Lacks family, who have been fighting for decades to ensure that their mother’s legacy is honored and that her cells are used ethically. The settlement also sends a message to other companies that use human cells without consent that they will be held accountable.

“This settlement is a long-awaited victory for the Lacks family,” said Ben Crump, one of the family’s lawyers. “It is a recognition of the harm that was done to Henrietta Lacks and her family, and it is a step towards ensuring that her cells are used ethically in the future.”

The settlement also includes a commitment from Thermo Fisher to create a fund to support research into cervical cancer, the disease that killed Henrietta Lacks.

“We are pleased to have reached a settlement with the Lacks family,” said Peter R. Jones, president of Thermo Fisher Scientific. “We believe that this settlement is in the best interests of all parties involved, and we are committed to working with the Lacks family to honor Henrietta Lacks’ legacy.”

The settlement is a significant step forward in the fight for justice for Henrietta Lacks and her family. It is a reminder that the exploitation of human cells without consent is unacceptable and that those who engage in this practice will be held accountable.

The settlement also sends a message to the scientific community that the use of human cells must be done ethically and with the consent of the donors.


1 min read

Physician-Entrepreneur Founded Company Has Raised $190M To Combat Health Inequity

Zing Health is a tech-enabled health insurance company that was founded in 2019 by two African American physician entrepreneurs, Eric E. Whitaker, MD, MPH, and Kenneth Alleyne, MD.

The Chicago-based company’s mission is to provide managed care Medicare Advantage plans that address social determinants of health to reduce healthcare disparities among historically underserved populations.

Dr. Eric E. Whitaker has more than 30 years of experience working in both the public and private sectors to create cutting-edge healthcare solutions for medically underserved populations.

He is also one of the first Black entrepreneurs to raise over $180 million in Chicago.

In this interview, Dr. Whitaker shares:

  • His thoughts on health equity and addressing racial disparities in healthcare
  • Almost going out of business during the height of the pandemic
  • His experience raising $190 million dollars
  • Advice for other entrepreneurs running a healthcare business
  • The most pressing health issue in the Black community

-Tony O. Lawson


4 mins read

Incredible Health, a Black-Owned Nurse Staffing Platform, Raises $80M and Grows to a $1.65B Company

Incredible Health is a Black owned staffing platform that helps nurses find their next permanent role, and employers hire permanent, specialized nurses in 20 days or less.

As a career marketplace for permanent healthcare workers, Incredible Health puts nurses in the driver’s seat. Hospitals apply directly to nurses rather than the other way around. The first and only platform to focus on permanent employees rather than contractors, Incredible Health is already used by over 600 top hospitals nationwide.

Last month, Incredible Health announced it has secured $80 million in Series B funding, bringing the company’s valuation to $1.65 billion.

Now the highest valued tech-enabled career marketplace in healthcare, the company has radically transformed not only how nurses are hired but the experience of nursing itself.

This new funding will support the company’s initiatives to help health systems and their employees manage surging patient care demand.

“Nurses are the backbone of the US healthcare system, and they deserve the well-staffed teams and tools to not only succeed, but also feel fulfilled in their careers,” said Iman Abuzeid M.D., CEO and co-founder of Incredible Health. “Our model has met the moment and changed the paradigm for both nurses and healthcare providers in the most challenging time in U.S. healthcare. We’re excited to accelerate our growth to affect even more change.”

incredible health
Incredible Health cofounders Iman Abuzeid and Rome Portlock.

Base10 Partners led the round as part of their Advancement Initiative, a fund designed to align the success of tech companies with wealth creation for underrepresented minorities.

Incredible Health achieved a milestone year in performance, reporting more than 500% increase in revenue in 2021. More than 10,000 nurses join the marketplace every week and the company has reduced the average time to hire to 14 days from the industry standard of 82 days.

Sixty percent of the top-ranked hospitals in the U.S., including Stanford Health Care, Cedars-Sinai Medical Center, NYU Langone Health, Northwestern Medicine and 600 more hospitals use Incredible Health for their permanent staffing needs.

Its offerings are more urgently needed than ever: the U.S. is on track to be one million nurses short by the end of 2023, and 75% of nursing student graduates cite staffing shortages as their main concern in entering the field.

Incredible Health will deploy its capital directly into rebuilding the shrinking nurse workforce. With the aim to continue expanding Incredible Health to new markets for health systems and nursing talent, the company will use this funding to:

  • Optimize every aspect of the hiring workflow with machine learning technology, including screening and matching, to an increasingly personalized and automated experience for both healthcare workers and employers
  • Support nurses and other healthcare workers over the course of their entire careers, beyond finding permanent jobs, including skill growth, scheduling services, mobility and relocation support, cross-training, and educational scholarships
  • Enhance Incredible Health’s tech-enabled nurse community with personalized advice and content ranking, ensuring that Incredible Health continues to be the largest online community of nurses and other healthcare workers
  • Expand and scale to 90% of the U.S. nurse workforce, and support healthcare worker roles beyond nursing that have critical shortages

Incredible Health has 180 remote employees in 35 states and continues to hire at a rapid pace.

To join Incredible Health’s expanding team, visit the careers page here.

-Tony O. Lawson

5 mins read

Black Nurse Launches The First Digital Community To Support Maternal Mental Health

Wolomi is the first online pregnancy community created by a Black nurse for women of color.  The app connects women of color on their pregnancy journey to information and mental health screening.

In recognition of Maternal Mental health month, we spoke to Wolomi founder, Layo George to learm more about her business and her mission to improve the pregnancy journey by connecting women of color to clinically accessible information, culturally sensitive health experts, mental health screenings, midwifery philosophy, & a supportive community!

What inspired you to start Wolomi?

While working as a delivery nurse in the Midwest. I saw firsthand the differences in the level of health care between white women and women of color.

Care gaps for women of color are an overwhelming reality, as they are three times more likely to die in pregnancy and postpartum depression. When I was pregnant with my child, I didn’t want to die, I wanted a safe and positive experience.

My experience was very positive because I created it myself, however, this is not a reality for all women of color. I wanted to help women navigate the system so they would have better pregnancy outcomes, joy and better care.


What are some of the effects of not addressing maternal health?

We have seen during the pandemic that women of color, especially Black women fare worse in the health system during their pregnancy period. We are basically not getting better at this.

The issue is more of the effects of not addressing it properly. Just because a solution is digital does not necessarily make it culturally competent and relevant for women of color.

The side effect of us not addressing maternal health appropriately means women of color are more likely to experience stress, suffer and die during a time that is supposed to be a joyful time.

What are some strategies mothers and mothers-to-be can use to combat maternal health challenges?

  • Make sure that you pick the right provider (doctor, midwife) that understands you, and that you trust.
  • Realize that you are a customer in the healthcare system, always ask questions, amplify the things you like and reject what you don’t.
  • Use tools like the Wolomi App to help you prep and find the words you need when going to your provider (doctor or midwife)
  • Trust your gut and yourself
  • Create a community around you. You can’t do it alone, and it is ok. There are great platforms like the Wolomi App where you can find moms like you on the journey.
  • Don’t be afraid to use a professional therapist especially when things get rough.

Do you feel that the pandemic has had an effect on maternal mental health?

Oh yes. At the beginning of the pandemic, we got a lot of messages from moms scared, especially with some of the restrictions that were placed in the birthing places.

Things constantly change and that can be hard for aspiring moms, moms-to-be, and new moms. Not only do they have to navigate constant changes, at times they have to do it in isolation.

Birthing people are being asked to shoulder a lot mentally.

What are some maternal health-related solutions that you would like to see implemented in the healthcare industry?

 We have a real shortage of culturally competent maternal health providers. The waitlist can be very long and sometimes it can be very expensive (if your insurance doesn’t cover the therapist you like, etc).

I would like to see more platforms that address the recruitment and training of culturally competent mental health providers.


Tony O. Lawson

Don’t miss any articles! Subscribe to our newsletter and follow us on Facebook, Instagram, LinkedIn & Twitter

2 mins read

17-Year-Old Imunique Triplett Completes Nursing Degree Before High School Graduation

Imunique Triplett is a 17-year-old Milwaukee resident who just earned her practical nursing diploma while still in high school.

She is one of the first to complete the nursing track as part of the M³ College Connections program.

M³ (pronounced M-cubed) allows Milwaukee Public School students to enroll in Milwaukee Area Technical College and University of Wisconsin-Milwaukee classes, earning credits that count toward their graduation from both high school and college with pathways including nursing, teaching, and general education.

Imunique says she had to juggle her three to four college classes and high school coursework simultaneously including during the height of the pandemic.

Her road to this achievement hasn’t been easy. Her great aunt and great uncle adopted her when she was 10 months to help provide a stable foundation for life and school.

“I work so hard because I’ve seen how people can struggle. I have seen my parents live from paycheck to paycheck and I knew that I wanted to change that narrative,” she said. “I have tried to surround myself with people who inspire me and that I can inspire.”

Students who complete the nursing track can become licensed practical nurses, who often work in extended care facilities or hospitals. They can continue their education to become registered nurses or nurse practitioners who have more responsibilities and higher salaries.

Imunique hopes to become a registered dnurse, but her teachers are confident she could become a nurse practitioner, the highest level of nursing.


Subscribe and Follow SHOPPE BLACK on Facebook, Instagram &Twitter

3 mins read

This $55 Million Fund Invests Exclusively in Black Owned Healthcare Startups

Jumpstart Nova is the first fund that invests exclusively in Black owned healthcare startups in the US.

The fund recently announced that it has raised $55 million from health care investors including Eli Lilly and Company, Cardinal Health, and Atrium Health, oversubscribing its initial $30 million target.

Black Owned Healthcare Startups
Marcus Whitney –  Founder and General Partner of Jumpstart Nova

The fund will invest in companies across health IT, digital health, tech-enabled services, diagnostic devices, biotech, medical device manufacturing, and consumer health and wellness, according to a press release.

Marcus Whitney is the founder and General Partner. He was inspired to create Jumpstart Nova as a solution to a central gap he saw in the marketplace. Jumpstart Nova is the newest in a family of funds managed by JHI, which he co-founded with Vic Gatto in 2015 in Nashville.

”The healthcare venture capital industry has missed out for decades on investing in America’s brilliant Black innovators, and this has been a loss for us all. Jumpstart Nova’s strong start and incredible group of limited partners validate the need to capitalize and support the vital solutions from this untapped talent base,” said Whitney, in a statement.

Jumpstart Nova is working to increase equity in the healthcare venture space by maintaining majority Black owned general partners, growing the number of Black VC limited partners and VC professionals, generating great returns and investing in Black founders and leaders at the forefront of healthcare innovation, the company said.

The fund’s initial portfolio companies are tackling healthcare issues like equitable access to clinical trials, bringing novel cell and gene therapies to market, helping families with autistic children get the therapeutic support they need, and seeking to mitigate the risk of life-threatening food allergy attacks, according to Whitney.

Companies qualifying for consideration for Seed or Series A investment will have at least one Black founder in a C-level position and holding a board seat.

Check sizes will generally range from $250K-$3MM and the fund will often lead rounds, in which cases it will require a board seat. Its investments will mostly be minority investments.

Tony O. Lawson

Subscribe and Follow SHOPPE BLACK on Facebook, Instagram Twitter